Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
| ▸ | SLC9A1 | P19634 | 5/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4134864 | 1.00 | KDM1A (0.59) | KDM1AHRH3HTR2AHTR2CHTR2B | |
| SCHEMBL4134734 | 0.85 | KDM1A (0.56) | KDM1AHRH3HTR2AHTR2CHTR2B | |
| SCHEMBL29302375 | 0.85 | KDM1A (0.56) | KDM1AHRH3HTR2AHTR2CHTR2B | |
| SCHEMBL6902985 | 0.85 | KDM1A (0.56) | KDM1AHRH3HTR2AHTR2CHTR2B | |
| SCHEMBL4134736 | 0.85 | KDM1A (0.56) | KDM1AHRH3HTR2AHTR2CHTR2B | |
| SCHEMBL25606213 | 0.83 | KDM1A (0.54) | KDM1AHRH3HTR2AHTR2CHTR2B | |
| SCHEMBL24737867 | 0.80 | SLC9A1 (0.71) | HTR2AHTR2CHTR2BSLC9A1PARP1 | |
| SCHEMBL15542072 | 0.80 | SLC9A1 (0.71) | HTR2AHTR2CHTR2BSLC9A1PARP1 | |
| SCHEMBL24737580 | 0.80 | SLC9A1 (0.71) | HTR2AHTR2CHTR2BSLC9A1PARP1 | |
| SCHEMBL15540612 | 0.80 | SLC9A1 (0.71) | HTR2AHTR2CHTR2BSLC9A1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203750-A1 | 5-HT2C Receptor Agonists as Anorectic Agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-13 | — | — | US | disclosed |
| WO-2007025144-A1 | 5-HT2C RECEPTOR AGONISTS AS ANORECTIC AGENTS | UNIVERSITY OF ILLINOIS - CHICAGO (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203750-A1 | 5-HT2C Receptor Agonists as Anorectic Agents | HTR2C, HTR2A, HTR5A | KDM1A 3105/4885HRH3 436/4885HTR2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.